RARE
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
Friday, September 9, 2022 BiopharmaWatch Research 1 min read Key Takeaway: Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
Price reaction · baseline $47.73 (2022-09-08 close) · hit after-hours · clean, no other RARE news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia
Full Press Release Details
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR.